Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12471630 | 0.60 | KMT2A (0.42) | KDM4EKMT2AOPRM1 | |
| SCHEMBL4104019 | 0.59 | KMT2A (0.41) | KDM4EKMT2AOPRM1 | |
| SCHEMBL854175 | 0.59 | KDM4E (0.41) | KDM4EKMT2AOPRM1 | |
| SCHEMBL31170659 | 0.58 | KDM4E (0.36) | KDM4EKMT2AOPRM1 | |
| SCHEMBL21553840 | 0.58 | KDM4E (0.44) | KDM4EKMT2AOPRM1 | |
| SCHEMBL12230984 | 0.57 | — | — | |
| SCHEMBL7677113 | 0.57 | — | — | |
| SCHEMBL825722 | 0.57 | KDM4E (0.38) | KDM4EKMT2AOPRM1 | |
| Hydrochloric Acid SCHEMBL23727033 | 0.57 | KDM4E (0.38) | KDM4EKMT2AOPRM1 | |
| SCHEMBL23727874 | 0.55 | CYP1A2 (0.38) | KDM4EKMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | disclosed |
| US-7737127-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-7427606-B2 | Method to reduce inflammatory response in transplanted tissue | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-7396825-B2 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7378400-B2 | Method to reduce an inflammatory response from arthritis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1496911-B1 | USE OF A COMBINATION COMPRISING A2A ADENOSINE RECEPTOR AGONISTS AND ANTI-PATHOGENIC AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIV VIRGINIA (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-04 | — | — | US | disclosed |
| US-7214665-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1746885-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATMENT OF DIABETIC NEPHROPATHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060100169-A1 | Method to reduce an inflammatory response from arthritis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-05-11 | — | — | US | disclosed |
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-24 | — | — | US | disclosed |
| WO-2005107463-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATMENT OF DIABETIC NEPHROPATHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | disclosed |
| EP-1496911-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1434782-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | University of Virginia Patent Foundation (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003086408-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | disclosed |
| WO-2003029264-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100169-A1 | Method to reduce an inflammatory response from arthritis | PDE4A, PDE4B, PDE7A | KDM4E 1705/4885KMT2A 3339/4885OPRM1 3039/4885 |
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | ADORA2A, ADORA3, PDE4A | KDM4E 1535/4885KMT2A 2621/4885OPRM1 834/4885 |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | KDM4E 3032/4885KMT2A 4262/4885OPRM1 1110/4885 |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | ADORA2A, PDE4A, PDE4B | KDM4E 2737/4885KMT2A 4304/4885OPRM1 1135/4885 |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | KDM4E 2505/4885KMT2A 1922/4885OPRM1 192/4885 |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | KDM4E 2505/4885KMT2A 1922/4885OPRM1 192/4885 |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | ADORA2A, ADORA1, ADORA3 | KDM4E 3528/4885KMT2A 2388/4885OPRM1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.